{"title":"Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma.","authors":"Connor Frey, Mahyar Etminan","doi":"10.1080/10428194.2025.2461663","DOIUrl":null,"url":null,"abstract":"<p><p>Clozapine is a cornerstone treatment for schizophrenia, though long-term use has been associated with significant adverse effects, including hematologic risks. This study analyzed FDA Adverse Event Reporting System (FAERS) data from 2003 to 2024 to assess the potential link between clozapine and lymphoma. Disproportionality analyses revealed elevated reporting odds ratios (RORs) for clozapine: Hodgkin lymphoma (HL) (3.76; 95% CI: 2.84-4.97) and non-Hodgkin lymphoma (NHL) (3.62; 95% CI: 2.88-4.54), while other antipsychotics showed no significant associations. Although causality cannot be established, the results underscore the need for targeted research into clozapine-associated risks and improved monitoring strategies to protect patients reliant on this medication. Further studies are essential to refine safety protocols and understand population-specific risks.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1129-1131"},"PeriodicalIF":2.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2461663","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Clozapine is a cornerstone treatment for schizophrenia, though long-term use has been associated with significant adverse effects, including hematologic risks. This study analyzed FDA Adverse Event Reporting System (FAERS) data from 2003 to 2024 to assess the potential link between clozapine and lymphoma. Disproportionality analyses revealed elevated reporting odds ratios (RORs) for clozapine: Hodgkin lymphoma (HL) (3.76; 95% CI: 2.84-4.97) and non-Hodgkin lymphoma (NHL) (3.62; 95% CI: 2.88-4.54), while other antipsychotics showed no significant associations. Although causality cannot be established, the results underscore the need for targeted research into clozapine-associated risks and improved monitoring strategies to protect patients reliant on this medication. Further studies are essential to refine safety protocols and understand population-specific risks.
期刊介绍：
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
